IP Library Granted Patent US 12,012,443
Granted Patent B2
US 12,012,443 · App. 17/166,903 · Granted Jun 18, 2024

Immunomodulatory fusion proteins and uses thereof

Inventors: Shannon K. Oda (Lake Forest Park, WA); Philip D. Greenberg (Mercer Island, WA); Thomas M. Schmitt (Seattle, WA)
Assignee: Fred Hutchinson Cancer Center
C07K14/70596A61K35/17C07K14/70503C07K14/70507C07K14/7051C07K14/70517C07K14/70521C07K14/70578C12N5/0636C12N5/0637C12N5/0638A61K38/00A61K48/00C07K2319/03C07K2319/74C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,012,443
App. No.
17/166,903
Granted
Jun 18, 2024
Kind
B2
Abstract

Described herein are immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. Some immunomodulatory fusion proteins as described comprise a SIRPα extracellular component and hydrophobic and intracellular components comprising transmembrane and/or signaling domains of a CD28, respectively. Such fusion proteins are capable of delivering a positive or costimulatory signal in response to a binding event that in a natural setting would result in an inhibitory signal. Uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease, are also described.

Claims (16)

1. A fusion protein comprising the amino acid sequence encoded by a nucleic acid molecule as set forth in any one of SEQ ID NOs.:19, 20, 22, and 23.

2. A fusion protein comprising the amino acid sequence set forth in any one of SEQ ID NOs.:42, 43, 45, and 46.

3. The fusion protein of claim 2 , comprising the amino acid sequence set forth in SEQ ID NO.:42.

4. The fusion protein of claim 2 , comprising the amino acid sequence set forth in SEQ ID NO.:43.

5. The fusion protein of claim 2 , comprising the amino acid sequence set forth in SEQ ID NO.:45.

6. The fusion protein of claim 2 , comprising the amino acid sequence set forth in SEQ ID NO.:46.

7. The fusion protein of claim 2 , consisting of the amino acid sequence set forth in SEQ ID NO.:42.

8. The fusion protein of claim 2 , consisting of the amino acid sequence set forth in SEQ ID NO.:43.

9. The fusion protein of claim 2 , consisting of the amino acid sequence set forth in SEQ ID NO.:45.

10. The fusion protein of claim 2 , consisting of the amino acid sequence set forth in SEQ ID NO.:46.

11. A nucleic acid molecule encoding a fusion protein, wherein the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs.:42, 43, 45, and 46.

12. A vector comprising a nucleic acid molecule that encodes a fusion protein, wherein the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs.:42, 43, 45, and 46.

13. A host cell comprising a nucleic acid molecule that encodes a fusion protein, wherein the fusion protein comprises the amino acid sequence set forth in any one of SEQ ID NOs.:42, 43, 45, and 46.

14. The host cell of claim 13 , wherein the host cell is a T cell.

15. The host cell of claim 13 , wherein the host cell is a CD4+ cell or a CD8+ T cell.

16. The host cell of claim 13 , wherein the host cell is an immune system cell.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Feb 28, 2024
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 066593/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2021
From: ODA, SHANNON K.; GREENBERG, PHILIP D.; SCHMITT, THOMAS M.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 057563/0308 →
Continuity (3)
Continuation 15555951
Provisional Application 62128979 · Mar 5, 2015
Related Publication 20210403532A1 · Dec 30, 2021